首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1597668

去活化疫苗市場報告：2030 年趨勢、預測與競爭分析

Inactivated Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2024年11月14日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

去活化疫苗的趨勢和預測

至2030年，全球去活化疫苗市場預計將達到545億美元，2024年至2030年的複合年成長率為5.4%。該市場的主要促進因素是對更方便、更有效的疫苗的需求不斷成長、政府大力推動疫苗接種以及感染疾病率的增加。全球去活化疫苗市場前景廣闊，醫院、居家醫療和專科診所市場充滿機會。

根據Lucintel的預測，按類型分類，由於對有效預防病毒感染的去活化疫苗的需求量很大，預計病毒疫苗在預測期內將出現高速成長。
在最終用途類別中，預計醫院將在預測期內呈現最高成長。這是因為作為常規免疫計劃的一部分，該機構向兒童注射的去活化疫苗數量有所增加。
從地區來看，亞太地區預計將在預測期內實現最高成長。這是由於感染疾病病例數量不斷增加以及該地區主要企業的存在。

去活化疫苗市場的策略性成長機會

去活化疫苗市場的市場分析確定了各個應用領域的成長機會。這些前景反映了不斷變化的全球健康趨勢和免疫接種的改進。

針對新興感染疾病的去活化疫苗的潛力：針對新興傳染病的去活化疫苗的開發預計將推動成長。對抗新出現的病原體對於國家健康安全和市場擴張至關重要。
去活化疫苗在慢性疾病管理中的潛力：正在研究去活化疫苗用於癌症和糖尿病等慢性疾病的管理。該應用提供了開發新疫苗和療法的機會。
去活化疫苗在兒科疫苗接種中的潛力：透過擴大兒童去活化疫苗的選擇，還有進一步的成長機會。這些疫苗可滿足兒童的特殊需求，並改善免疫和疾病預防。
去活化疫苗在旅遊和旅遊業的潛力：針對旅行相關疾病的去活化疫苗的需求正在增加。隨著國際旅行的恢復，保護人們免受當地流行病侵害的疫苗的需求不斷增加。
去活化疫苗在生物防禦中的潛力：人們對開發用於生物恐怖主義防禦的去活化疫苗也越來越感興趣。這些疫苗對於打擊生物恐怖主義和保護社會至關重要。

這些成長機會定義了去活化疫苗的廣泛應用，提高了其適銷性並推動了醫療保健系統的進步和技術改進。

去活化疫苗市場的促進因素與挑戰

去活化疫苗市場受到各種市場促進因素和挑戰的影響，包括技術、經濟和監管因素。了解這些因素是認知市場動態的關鍵。

推動去活化疫苗市場的因素是：

技術進步：疫苗製造領域的最新創新，例如新佐劑和其他配方，正在推動市場發展。這些改進具有效率和安全性優勢，使疫苗對患者和醫療保健提供者都更加有利。
疫苗需求增加：傳染病發病率的上升和衛生組織的宣傳活動正在推動對去活化疫苗的需求。這一趨勢為市場擴張和增加疫苗開發資金提供了機會。
監管支援：有利的法規環境對於疫苗核准和市場准入至關重要。有效的法規和指導方針將消除延誤，並使新的去活化疫苗更有效地推向市場。
改善醫療基礎設施：加強儲存和分配系統等醫療基礎設施將有助於更有效地管理去活化疫苗。這個網路對於到達服務不足的地區至關重要。
研發投資：研發投資的增加正在徹底改變疫苗的有效性。正在進行的疫苗配方研究可滿足新出現疾病的需求。

去活化疫苗市場面臨的挑戰包括：

製造成本高：開發和製造無活性疫苗的成本仍然很高。這些高成本可能會影響定價和可用性，特別是對於低收入者。
市場競爭：疫苗生產商之間的激烈競爭給價格帶來了下行壓力，迫使企業不斷更新產品以保持競爭力。

去活化疫苗市場正在受到技術進步、需求成長和支持性法規結構等關鍵促進因素以及與合規性、製造成本和競爭相關的挑戰的影響。這些因素的作用對於市場開拓和動態至關重要。

成長機會分析
- 按類型分類的全球去活化疫苗市場成長機會
- 全球去活化疫苗市場成長機會（依最終用途）
- 全球去活化疫苗市場成長機會（按地區）
全球去活化疫苗市場的新趨勢
戰略分析
- 新產品開發
- 全球去活化疫苗市場產能擴張
- 全球去活化疫苗市場的併購和合資企業
- 認證和許可

第7章主要企業概況

Pfizer
Sanofi
GlaxoSmithKline
Merck
AstraZeneca
Johnson & Johnson
CSL Behring

簡介目錄

Inactivated Vaccine Trends and Forecast

The future of the global inactivated vaccine market looks promising with opportunities in the hospital, home care, and specialty clinic markets. The global inactivated vaccine market is expected to reach an estimated $54.5 billion by 2030 with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are the rising demand for more convenient and effective vaccines, supportive government initiatives to promote vaccination, and the increasing prevalence of infectious diseases.

Lucintel forecasts that, within the type category, viral is expected to witness higher growth over the forecast period due to significant demand for inactivated vaccines given to their effectiveness at preventing viral infections.
Within the end-use category, the hospital is expected to witness the highest growth over the forecast period due to the increasing number of inactivated vaccinations being administered to children in this facility as part of their regular immunization program.
In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the augmenting cases of infectious diseases and the presence of key players in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Inactivated Vaccine Market

Certain key trends can be observed in the inactivated vaccine market that are shaping the industry. These trends show improvements in technology, transformations in health needs, and changes in the regulatory environment.

Emerging Trends in Adjuvant Technology: New adjuvants are being added to existing inactivated vaccines to improve the immune response. These developments are important for enhancing vaccines and providing wider coverage against evolving pathogens.
Increasing Focus on Vaccine Accessibility: There is an increasing trend to provide inactivated vaccines to all parts of the world, particularly underprivileged countries. This includes actions to increase production and distribution to ensure fair provision of vital vaccines.
Combination Vaccines: Combination inactivated vaccines for several diseases are becoming more popular. These vaccines help economize immunization schedules and improve patient adherence by reducing the number of doses.
Incorporation of Digital Health Tools: Monitoring tools, such as tracking apps and digital vaccination records, are being incorporated with inactivated vaccines. These tools help track vaccine placement and improve patient management.
Stronger Focus on R&D: There is a higher demand for investment in research and development of inactivated vaccines. This trend is driven by the emergence of novel infectious diseases and the need to improve currently available vaccines.

These trends are driving innovation, expanding the role of vaccines, and increasing the efficacy of inactivated vaccines, shaping the future of global vaccination programs.

Recent Developments in the Inactivated Vaccine Market

The inactivated vaccine market has undergone significant changes, indicating advancements in combating diseases with vaccines.

Expanding the Inactivated Vaccine Pipeline: Recent approvals for inactivated vaccines targeting new pathogens have expanded the market. These vaccines have a better safety profile and address unmet medical needs.
Streamlined Manufacturing Methods: New production technologies are enabling the efficient manufacture of inactivated vaccines. These innovations help lower prices and make vaccines more accessible, especially in marginalized areas.
Application of New Quality Vaccine Adjuvants: Efforts are underway to develop new adjuvants that are more efficient and stable than previous ones. These changes are expected to enhance immune memory and reduce the need for boosting.
Improvement of Distribution Channels: Efforts have increased the distribution of inactivated vaccines globally. Improved logistics and collaborations are enabling vaccines to reach distant and underserved populations.
Raising Public Health Administration: Public health efforts by governments and organizations are increasing to promote vaccination. These initiatives include education and outreach campaigns alongside immunization efforts to boost vaccine uptake.

These developments enhance the potency of vaccines, lower development costs, and increase accessibility, fostering progress and efficiency in the inactivated vaccine market.

Strategic Growth Opportunities for Inactivated Vaccine Market

Market analysis of the inactivated vaccine market identifies growth opportunities in various application areas. These prospects reflect changing trends in global health and improvements in vaccinations.

Potential of Inactivated Vaccines for Emerging Infectious Diseases: Developing inactivated vaccines for emerging infectious diseases is expected to drive growth. The fight against new pathogens is critical for national health security and market expansion.
Potential of Inactivated Vaccines for Chronic Disease Management: Inactivated vaccines are being studied for managing chronic conditions like cancer and diabetes. This application offers opportunities for developing new vaccines and therapeutic agents.
Potential of Inactivated Vaccines in Pediatric Vaccination: There are additional growth opportunities by expanding inactivated vaccine options for children. These vaccines address specific needs in children, improving immunization and disease prevention.
Potential of Inactivated Vaccines in Travel and Tourism: There is growing demand for inactivated vaccines for travel-related diseases. As international travel resumes, there is an increased need for vaccines that protect populations from local endemic diseases.
Potential of Inactivated Vaccines in Biodefense: There is also growing interest in developing inactivated vaccines for bioterrorism defense. These vaccines are vital for combating bioterrorism and protecting society.

These growth opportunities define the wide range of applications for inactivated vaccines, enhancing their marketability and driving progress in healthcare systems and technological improvements.

Inactivated Vaccine Market Driver and Challenges

The market for inactivated vaccines is influenced by a variety of drivers and challenges, including technological, economic, and regulatory factors. Understanding these factors is key to recognizing market dynamics.

The factors driving the inactivated vaccine market include:

Technological Advancements: Recent innovations in vaccine manufacturing, such as new adjuvants and other formulations, are boosting the market. These improvements offer advantages in efficiency and safety, making vaccines more favorable for both patients and healthcare providers.
Increased Demand for Vaccines: The rising incidence of communicable diseases and campaigns by health organizations are fueling demand for inactivated vaccines. This trend presents opportunities for market expansion and increased funding for vaccine development.
Regulatory Support: A favorable regulatory environment is essential for the approval and market entry of vaccines. Effective regulations and guidelines help eliminate delays, allowing new inactivated vaccines to reach the market more efficiently.
Healthcare Infrastructure Improvements: Enhancements in healthcare infrastructure, such as storage and distribution systems, help administer inactivated vaccines more effectively. This network is crucial for reaching geographically underserved areas.
Investment in R&D: Increased investment in research and development is driving innovation in vaccine efficacy. Ongoing investigations into vaccine formulations are addressing the needs of new diseases.

Challenges in the inactivated vaccine market include:

High Production Costs: Non-live vaccines remain expensive to develop and manufacture. These high costs can impact pricing and accessibility, especially in low-income areas.
Market Competition: Intense competition among vaccine manufacturers is exerting downward pressure on prices and forcing companies to continuously update their products to remain competitive.

The inactivated vaccine market is shaped by significant drivers, such as technological advances, rising demand, and supportive regulatory frameworks, as well as challenges related to compliance, production costs, and competition. The role of these factors is crucial in the development and dynamics of the market.

List of Inactivated Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies inactivated vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the inactivated vaccine companies profiled in this report include-

Pfizer
Sanofi
GlaxoSmithKline
Merck
Astrazeneca
Johnson & Johnson
CSL Behring

Inactivated Vaccine by Segment

The study includes a forecast for the global inactivated vaccine by type, end use, and region.

Inactivated Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

Viral
Bacterial
Others

Inactivated Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

Hospitals
Homecare
Specialty Clinics
Others

Inactivated Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Inactivated Vaccine Market

The inactivated vaccine market has made significant progress due to continuous research, policy changes, and global health interest. This is particularly true in countries like the USA, China, India, Germany, and Japan, which share a common goal of improving vaccine safety, efficacy, and availability.

United States: Recent updates in the U.S. include the approval of new inactivated vaccines to address gaps in immunization for emerging infectious diseases. These vaccines are designed to be more efficient, safer, and cost-effective to manufacture.
China: China has made significant strides in developing inactivated vaccines for COVID-19 and other infectious diseases. The country is increasing production and enhancing distribution to meet both national and global demands.
India: India is upgrading its vaccine manufacturing capacity to support the production and use of inactivated vaccines for various diseases. Local manufacturers are aiming to provide low-cost vaccines and improve access in rural communities.
Japan: Japan has recently introduced new inactivated vaccines for seasonal flu and other viral infections. The country is focusing on improving vaccine safety, effectiveness, and maintaining high manufacturing quality.

Features of the Global Inactivated Vaccine Market

Market Size Estimates: Inactivated vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Inactivated vaccine market size by type, end use, and region in terms of value ($B).

Regional Analysis: Inactivated vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the inactivated vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the inactivated vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the inactivated vaccine market by type (viral, bacterial, and others), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Inactivated Vaccine Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Inactivated Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Inactivated Vaccine Market by Type
- 3.3.1: Viral
- 3.3.2: Bacterial
- 3.3.3: others
3.4: Global Inactivated Vaccine Market by End Use
- 3.4.1: Hospitals
- 3.4.2: Homecare
- 3.4.3: Specialty Clinics
- 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Inactivated Vaccine Market by Region
4.2: North American Inactivated Vaccine Market
- 4.2.1: North American Market by Type: Viral, Bacterial, and others
- 4.2.2: North American Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
4.3: European Inactivated Vaccine Market
- 4.3.1: European Market by Type: Viral, Bacterial, and others
- 4.3.2: European Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
4.4: APAC Inactivated Vaccine Market
- 4.4.1: APAC Market by Type: Viral, Bacterial, and others
- 4.4.2: APAC Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
4.5: ROW Inactivated Vaccine Market
- 4.5.1: ROW Market by Type: Viral, Bacterial, and others
- 4.5.2: ROW Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Inactivated Vaccine Market by Type
- 6.1.2: Growth Opportunities for the Global Inactivated Vaccine Market by End Use
- 6.1.3: Growth Opportunities for the Global Inactivated Vaccine Market by Region
6.2: Emerging Trends in the Global Inactivated Vaccine Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Inactivated Vaccine Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Inactivated Vaccine Market
- 6.3.4: Certification and Licensing